Nexavar for HCC
- + Text Zoom

Nexavar — Demonstrated a Statistically Significant Advantage in Overall Survival (OS) vs Placebo in HCC1

Nexavar Chart Demonstrates a Statistically Significant Advantage in Overall Survival (OS) vs Placebo in HCC

CI=confidence interval, HR=hazard ratio.
aStatistically significant because the P value was below the prespecified O'Brien-Fleming stopping boundary of .0077.


Data from SHARP, a double-blind, randomised, placebo-controlled, multicentre, phase III trial that compared Nexavar 400 mg bid (n=299) to placebo (n=303) in patients with HCC. Additional informations about the pivotal study: The SHARP Trial.

  • 44% survival at 1 year vs 33% with placebo1

Next: Overview of HCC
 
Term
Explanation for term.